Craig C. Hopkinson - 06 Feb 2025 Form 4 Insider Report for Alkermes plc. (ALKS)

Role: EVP R&D, Chief Medical Officer
Signature: /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Issuer symbol: ALKS
Transactions as of: 06 Feb 2025
Transactions value $: -$473,455
Form type: 4
Filing time: 07 Feb 2025, 20:31:42
Previous filing: 31 Jan 2025
Next filing: 14 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALKS	Ordinary Shares	Award		+34.4K	+77.65%		78.7K	06 Feb 2025	Direct	F1
transaction	ALKS	Ordinary Shares	Tax liability	-$473K	-15.1K	-19.17%	$31.39	63.6K	06 Feb 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs.

Content

These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs.